{"id":"NCT00789737","sponsor":"Daiichi Sankyo","briefTitle":"Welchol as Monotherapy for Type 2 Diabetes Mellitus","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Welchol as Monotherapy for Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2011-12","completion":"2011-12","firstPosted":"2008-11-13","resultsPosted":"2014-01-22","lastUpdate":"2014-02-27"},"enrollment":357,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Welchol","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Welchol","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The current study investigates Welchol as monotherapy to improve glycemic control in subjects with Type 2 Diabetes Mellitus not adequately controlled with diet and exercise alone. The study will evaluate if Welchol monotherapy for Type 2 Diabetes Mellitus will be safe, well tolerated and efficacious.","primaryOutcome":{"measure":"Percent Change in Hemoglobin A1c","timeFrame":"24 week","effectByArm":[{"arm":"Welchol","deltaMin":-0.41,"sd":0.091},{"arm":"Placebo","deltaMin":-0.14,"sd":0.091}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0369"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":11},"locations":{"siteCount":107,"countries":["United States"]},"refs":{"pmids":["24356792"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":175},"commonTop":["urinary tract infection","headache","nasopharyngitis","diabetes mellitus","diarrhoea"]}}